Inspire Investing LLC Purchases 680 Shares of Glaukos Corporation $GKOS

Inspire Investing LLC raised its position in shares of Glaukos Corporation (NYSE:GKOS) by 17.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,638 shares of the medical instruments supplier’s stock after purchasing an additional 680 shares during the quarter. Inspire Investing LLC’s holdings in Glaukos were worth $479,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GKOS. SG Americas Securities LLC raised its position in shares of Glaukos by 35.2% during the 1st quarter. SG Americas Securities LLC now owns 4,924 shares of the medical instruments supplier’s stock valued at $485,000 after purchasing an additional 1,283 shares during the period. Handelsbanken Fonder AB increased its stake in Glaukos by 25.2% in the 1st quarter. Handelsbanken Fonder AB now owns 18,400 shares of the medical instruments supplier’s stock worth $1,811,000 after buying an additional 3,700 shares in the last quarter. Elevation Point Wealth Partners LLC raised its holdings in Glaukos by 78.2% during the first quarter. Elevation Point Wealth Partners LLC now owns 3,221 shares of the medical instruments supplier’s stock valued at $317,000 after acquiring an additional 1,413 shares during the period. Exchange Traded Concepts LLC raised its holdings in Glaukos by 27.5% during the first quarter. Exchange Traded Concepts LLC now owns 6,626 shares of the medical instruments supplier’s stock valued at $652,000 after acquiring an additional 1,430 shares during the period. Finally, Avior Wealth Management LLC lifted its position in shares of Glaukos by 30.1% in the first quarter. Avior Wealth Management LLC now owns 3,384 shares of the medical instruments supplier’s stock valued at $333,000 after acquiring an additional 782 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. William Blair upgraded Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research report on Wednesday, October 8th. UBS Group upped their target price on shares of Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Citigroup reduced their price target on shares of Glaukos from $140.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. Finally, Zacks Research cut shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus target price of $118.00.

Glaukos Price Performance

Shares of Glaukos stock opened at $82.55 on Monday. The stock has a market cap of $4.73 billion, a price-to-earnings ratio of -50.03 and a beta of 0.76. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The stock has a 50 day moving average price of $87.95 and a 200-day moving average price of $92.61. Glaukos Corporation has a one year low of $77.10 and a one year high of $163.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The company had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. During the same period last year, the company earned ($0.52) earnings per share. Glaukos’s revenue was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. Equities analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.